CEMIP and hepatocellular carcinoma: Studies showed that CEMIP was essential for maintaining cell metastasis and EMT in sorafenib-resistant hepatocellular carcinoma cells (16), and also demonstrated that CEMIP trigged acquired resistance to selumetinib in colorectal cancer cells (17).